About Us | Contact

Dr. Gerard A. Compito

Diagnostic Radiology University Medical Center Of Princeton At Plainsboro NPI1871527358
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$300,642.50
from 20 payments in the last 6 years

Total Cash or Cash Equivalent

$300,642.50
from 20 payments in the last 6 years

Total In-kind Items & Services

$0.00
from 0 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
05/07/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $480.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848717851
03/03/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $60.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848680643
09/03/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $660.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848677197
08/02/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $600.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848677195
04/08/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $60.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848657405
11/05/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $87.50 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848562007
12/07/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $780.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848542395
11/05/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $867.50 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848501673
07/06/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $540.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848489727
01/04/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $60.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848466527
10/06/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $720.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848442119
06/08/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $300.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848309473
02/04/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $120.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848309471
07/06/2021 Research Cash or cash equivalent Biological $150.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study Multi-Center Phase II Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain Treated with Nivolumab in Combinatiion with Ipilimumab followed by Nivolumab Monotherapy
Payment Record ID 819889611
11/06/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $175.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 747849077
07/08/2020 Research Cash or cash equivalent Biological $6300.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study Multi-Center Phase II Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain Treated with Nivolumab in Combinatiion with Ipilimumab followed by Nivolumab Monotherapy
Payment Record ID 736765481
01/28/2019 Research Cash or cash equivalent Biological $150170.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study Phase IIB 1L GBM Methylated nivo mono chemo RT
Payment Record ID 639764955
03/21/2019 Research Cash or cash equivalent Biological $41775.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study Multi-Center Phase II Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain Treated with Nivolumab in Combinatiion with Ipilimumab followed by Nivolumab Monotherapy
Payment Record ID 639764793
12/20/2018 Research Cash or cash equivalent Biological $49212.50 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study Phase IIB 1L GBM Methylated nivo mono chemo RT
Payment Record ID 618456953
07/02/2018 Research Cash or cash equivalent Biological $47525.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study Multi Center Phase II Open Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain Treated with Nivolumab in Combinatiion with Ipilimumab followed by Nivolumab Monotherapy
Payment Record ID 618456919
;